Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 19.26 SEK -0.1% Market Closed
Market Cap: 663.5m SEK
Have any thoughts about
Orexo AB?
Write Note

Orexo AB
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Orexo AB
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Orexo AB
STO:ORX
Cash & Cash Equivalents
kr114.9m
CAGR 3-Years
-42%
CAGR 5-Years
-32%
CAGR 10-Years
-9%
Calliditas Therapeutics AB
STO:CALTX
Cash & Cash Equivalents
kr797.3m
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Cash & Cash Equivalents
kr2.8B
CAGR 3-Years
86%
CAGR 5-Years
70%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Cash & Cash Equivalents
kr170m
CAGR 3-Years
-49%
CAGR 5-Years
34%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Cash & Cash Equivalents
kr111.3m
CAGR 3-Years
-26%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Cash & Cash Equivalents
kr911.3m
CAGR 3-Years
25%
CAGR 5-Years
51%
CAGR 10-Years
N/A
No Stocks Found

Orexo AB
Glance View

Market Cap
663.5m SEK
Industry
Pharmaceuticals

Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

ORX Intrinsic Value
39.21 SEK
Undervaluation 51%
Intrinsic Value
Price

See Also

What is Orexo AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
114.9m SEK

Based on the financial report for Sep 30, 2024, Orexo AB's Cash & Cash Equivalents amounts to 114.9m SEK.

What is Orexo AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-9%

Over the last year, the Cash & Cash Equivalents growth was -38%. The average annual Cash & Cash Equivalents growth rates for Orexo AB have been -42% over the past three years , -32% over the past five years , and -9% over the past ten years .

Back to Top